Anti-inflammatory effect of palmitoylethanolamide on human adipocytes

Obesity

Volumn 17, Issue 3, 2009, Pages 431-438

  Hoareau, Laurence ^a   Buyse, Marion ^b   Festy, Franck ^a   Ravanan, Palaniyandi ^a   Gonthier, Marie Paule ^a   Matias, Isabel ^c   Petrosino, Stefania ^c   Tallet, Frank ^d   D'Hellencourt, Christian Lefebvre ^a   Cesari, Maya ^a   Di Marzo, Vincenzo ^c   Roche, Régis ^a  

^a UNIVERSITÉ DE LA RÉUNION   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CNR   (Italy)

^d Centre Hospitalier Departemental Felix Guyon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PALMIDROL; PALMITIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ADIPOCYTE; ADULT; ANIMAL; ANIMAL MODEL; ARTICLE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE; MOUSE STRAIN;

ADAM PROTEINS; ADIPOCYTES; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED STRAINS; MIDDLE AGED; MODELS, ANIMAL; NF-KAPPA B; PALMITIC ACIDS; PPAR ALPHA; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 60849113410     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.591     Document Type: Article

References (45)

1. Bès-Houtmann S, Roche R, Hoareau L et al. Presence of functional TLR2 and TLR4 on human adipocytes. Histochem Cell Biol 2007;127: 131-137.
2. Hoareau L, Ravanan P, Gonthier MP et al. Effect of PEA on LPS inflammatory action in human adipocytes. Cytokine 2006;34:291-296.
3. Coenen KR, Gruen ML, Chait A, Hasty AH. Diet-induced increases in adiposity, but not plasma lipids, promote macrophage infiltration into white adipose tissue. Diabetes 2007;56:564-573.
4. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830.
5. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112: 1796-1808.
6. Gonthier MP, Hoareau L, Festy F et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 2007;15:837-845.
7. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 2007;173:21-30.
8. Matias I, Gonthier MP, Petrosino S et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 2007;152:676-690.
9. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-281.
10. Darmani NA, Izzo AA, Degenhardt B et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 2005;48:1154-1163.
11. Di Marzo V, Melck D, De Petrocellis L, Bisogno T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat 2000;61:43-61.
12. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 2001;419:191-198.
13. Lo Verme J, Fu J, Astarita G et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-19.
14. Berdyshev E, Boichot E, Corbel M, Germain N, Lagente V. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci 1998;63:PL125-PL129.
15. Dandona P, Weinstock R, Thusu K et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998;83:2907-2910.
16. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
17. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-4858.
18. Di Marzo V, Goparaju SK, Wang L et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825.
19. Ajuwon KM, Spurlock ME. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005;288: R1220-R1225.
20. Suganami T, Tanimoto-Koyama K, Nishida J et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007;27:84-91.
21. Laurencikiene J, van Harmelen V, Arvidsson Nordstrom E et al. NF-{kappa}B is important for TNF-{alpha}-induced lipolysis in human adipocytes. J Lipid Res 2007;48:1069-1077.
22. Lambert DM, DiPaolo FG, Sonveaux P et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1999;1440:266-274.
23. Moro MA, Hurtado O, Cardenas A et al. Expression and function of tumour necrosis factor-alpha-converting enzyme in the central nervous system. Neurosignals 2003;12:53-58.
24. Armstrong L, Godinho SI, Uppington KM, Whittington HA, Millar AB. Contribution of TNF-alpha converting enzyme and proteinase-3 to TNF-alpha processing in human alveolar macrophages. Am J Respir Cell Mol Biol 2006;34:219-225.
25. Kawaguchi M, Mitsuhashi Y, Kondo S. Localization of tumour necrosis factor-alpha converting enzyme in normal human skin. Clin Exp Dermatol 2004;29:185-187.
26. Di Marzo V, Bisogno T, De Petrocellis L et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 1999;264:258-267.
27. Tataranni PA, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 2005;54:917-927.
28. Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 2004;6:424-431.
29. Bachur NR, Masek K, Melmon KL, Udenfriend S. Fatty acid amides of ethanolamine in mammalian tissues. J Biol Chem 1965;240: 1019-1024.
30. Giuffrida A, Piomelli D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett 1998;422:373-376.
31. Giuffrida A, Rodriguez de Fonseca F, Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem 2000;280:87-93.
32. Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 2002;9:663-674.
33. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000;108:169-190.
34. Di Marzo V, De Petrocellis L, Sepe N, Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 1996;316:977-984.
35. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 1997;272:3315-3323.
36. Matias I, Pochard P, Orlando P et al. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 2002;269:3771-3778.
37. Walker JM, Krey JF, Chu CJ, Huang SM. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 2002;121: 159-172.
38. Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-2072.
39. Shi H, Kokoeva MV, Inouye K et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3025.
40. Tsuboi K, Takezaki N, Ueda N. The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 2007;4:1914-1925.
41. Robertshaw HJ, Brennan FM. Release of tumour necrosis factor alpha (TNFalpha) by TNFalpha cleaving enzyme (TACE) in response to septic stimuli in vitro. Br J Anaesth 2005;94:222-228.
42. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7:438-455.
43. Tellier E, Canault M, Rebsomen L et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res 2006;312:3969-3980.
44. Grassme H, Riethmuller J, Gulbins E. Biological aspects of ceramideenriched membrane domains. Prog Lipid Res 2007;46:161-170.
45. Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 2000;406:R5-R7.